Gramicidin A 是 Gramicidin 的一种肽成分,是一种最初从 B. brevis 中分离得到的抗生素(antibiotic)混合物,作为一种高度疏水的通道形成离子载体,它能在人工膜中形成一价阳离子可渗透的通道,并诱导缺氧诱导因子 1α (HIF-1α) 的降解。
产品编号: MS-S71432 纯度: 96.94% CAS No.: 11029-61-1 分子式: C99H140N20O17 分子量: 1882.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

Gramicidin A 是 Gramicidin 的一种肽成分,是一种最初从 B. brevis 中分离得到的抗生素(antibiotic)混合物,作为一种高度疏水的通道形成离子载体,它能在人工膜中形成一价阳离子可渗透的通道,并诱导缺氧诱导因子 1α (HIF-1α) 的降解。

生物实验数据

生物活性 Gramicidin A is a peptide component of Gramicidin and an antibiotic mixture originally isolated from B. brevis that, as a highly hydrophobic channel-forming ionophore, forms monovalent cation-permeable channels in artificial membranes and induces the degradation of hypoxia-inducible factor 1α (HIF-1α).
IC50 & Target Caki-1 cells:0.228 μM, SN12C:0.104 μM, A498 cells:0.420 μM, 786-O cells:0.430 μM, ACHN cells:0.783
体外研究
(In Vitro)

Gramicidin A displays potent broad-spectrum antibiotic activity against Gram-positive strains, even multidrug-resistant strains.
Gramicidin A has the disadvantage of high hemolytic activity.
Gramicidin A (0.1 nM-10 μM, 72 h) reduces the viability of RCC cell lines and affects cell viability comparable to Monensin (MS-V97985).
Gramicidin A cellular sensitivity is significantly altered by neither VHL nor HIF-1α expression.
Gramicidin A (1 and 10 μM, 48 or 72 h) induces nonapoptotic cell death in RCC cells.
Gramicidin A (0-10 μM, 24 h) depletes cellular energy and induces metabolic dysfunction in RCC cells.
Gramicidin A (0-1 μM, 24-72 h) reduces HIF-1α and HIF-2α protein expression, reduces HIF transcriptional activity and target gene expression (24 h)

Cell Viability Assay

Cell Line: A498, 786-O, Caki-1, SN12C, ACHN, UMRC6, UMRC6+VHL, HEK293T+pcDNA3, HEK293T+HA-HIF-1α, HEK293T+HA-HIF-1α-mut
Concentration: 0.1 nM-10 μM
Incubation Time: 72 h
Result: Reduced the viability with IC50s of 0.420, 0.430, 0.228, 0.104, 0.783, 0.253, 0.425, 0.057, 0.058 and 0.067 μM against A498, 786-O, Caki-1, SN12C, ACHN, UMRC6, UMRC6+VHL, HEK293T+pcDNA3, HEK293T+HA-HIF-1α, HEK293T+HA-HIF-1α-mut cells, respectively.

Western Blot Analysis

Cell Line: 786-O, SN12C, Caki-1, ACHN
Concentration: 1 and 10 μM or 0.1, 0.5 and 1.0 μM
Incubation Time: 24, 48 or 72 h
Result: PARP cleavage was not detected. Increased the phosphorylation of AMPKα and its substrate ACC at both 24 and 48 hours. Reduced HIF-1α and HIF-2α protein expression. Hypoxic expression of CA-IX, GLUT-1, and GAPDH were all decreased in a dose-dependent manner.

RT-PCR

Cell Line: SN12C, Caki-1, ACHN
Concentration: 0.1, 0.5 and 1.0 μM
Incubation Time: 24 h
Result: Significantly altered transcript expression for only HIF-2α in SN12C cells.
体内研究
(In Vivo)

Gramicidin A (0.11 mg/kg; intratumoral injection; twice weekly for 14 days) inhibits the growth of RCC tumor xenografts.
Gramicidin A (0.22 mg/kg; intratumoral injection; thrice weekly for 26 days) inhibits the growth and angiogenesis of VHL-expressing RCC tumor xenografts.

Animal Model: Female hairless Nu/J mice, 6- to 8-week old, injected subcutaneously with a suspension of SN12C cells (1.0 × 106) in a 50% growth factor–reduced Matrigel solution
Dosage: 0.11 mg/kg body weight
Administration: Intratumoral injection, twice weekly for 14 days
Result: The average tumor mass was reduced by approximately 40% without significant toxicity.
Animal Model: Female hairless 6- to 8-week-old Nu/J mice, injected subcutaneously with a suspension of Caki-1-td-Tomato cells (1.5 × 106) in a 50% growth factor-reduced Matrigel solution.
Dosage: 0.22 mg/kg
Administration: Intratumoral injection, thrice weekly for 26 days
Result: Inhibited tumor growth. HIF-2α and GAPDH protein expression was substantially reduced.
性状 固体
颜色 White to off-white

化学信息

分子量 1882.29
分子式 C99H140N20O17
CAS No. 11029-61-1

储存&溶解度

溶解度信息
DMSO: Soluble
H2O: Slightly soluble
Ethanol: Soluble
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础